Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMMB NASDAQ:MTEX NASDAQ:PHXM NASDAQ:SHPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMMBChemomab Therapeutics$1.54+2.7%$1.71$1.35▼$4.92$11.09M0.6260,513 shs15,872 shsMTEXMannatech$5.20-3.2%$5.07$3.80▼$12.45$10.04M0.7225,166 shs35,106 shsPHXMPHAXIAM Therapeutics$3.10$3.10$2.50▼$13.00$10.58M2.352,472 shsN/ASHPHShuttle Pharmaceuticals$3.68-4.3%$6.62$3.16▼$55.90$2.34M0.18217,776 shs63,877 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMMBChemomab Therapeutics-0.66%-8.54%-25.74%-5.66%-68.22%MTEXMannatech-0.56%-1.10%+22.88%-23.18%-42.97%PHXMPHAXIAM Therapeutics0.00%0.00%0.00%0.00%0.00%SHPHShuttle Pharmaceuticals+9.09%-5.88%-34.05%-57.16%-89.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMMBChemomab Therapeutics$1.54+2.7%$1.71$1.35▼$4.92$11.09M0.6260,513 shs15,872 shsMTEXMannatech$5.20-3.2%$5.07$3.80▼$12.45$10.04M0.7225,166 shs35,106 shsPHXMPHAXIAM Therapeutics$3.10$3.10$2.50▼$13.00$10.58M2.352,472 shsN/ASHPHShuttle Pharmaceuticals$3.68-4.3%$6.62$3.16▼$55.90$2.34M0.18217,776 shs63,877 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMMBChemomab Therapeutics-0.66%-8.54%-25.74%-5.66%-68.22%MTEXMannatech-0.56%-1.10%+22.88%-23.18%-42.97%PHXMPHAXIAM Therapeutics0.00%0.00%0.00%0.00%0.00%SHPHShuttle Pharmaceuticals+9.09%-5.88%-34.05%-57.16%-89.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMMBChemomab Therapeutics 2.00Hold$25.001,523.38% UpsideMTEXMannatech 1.00SellN/AN/APHXMPHAXIAM Therapeutics 0.00N/AN/AN/ASHPHShuttle Pharmaceuticals 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest SHPH, CMMB, PHXM, and MTEX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/15/2026SHPHShuttle Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)6/11/2026MTEXMannatech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/1/2026SHPHShuttle Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)5/26/2026MTEXMannatech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/18/2026SHPHShuttle Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)5/8/2026CMMBChemomab Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/4/2026SHPHShuttle Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMMBChemomab TherapeuticsN/AN/AN/AN/A$2.00 per shareN/AMTEXMannatech$108.04M0.09N/AN/A($2.75) per share-1.89PHXMPHAXIAM TherapeuticsN/AN/AN/AN/A$7.98 per shareN/ASHPHShuttle PharmaceuticalsN/AN/AN/AN/A$11.14 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMMBChemomab Therapeutics-$8.99M-$2.22N/AN/AN/AN/A-89.03%-79.68%8/13/2026 (Estimated)MTEXMannatech-$15.21M-$6.71N/AN/AN/A-11.97%-2,383.34%-40.24%N/APHXMPHAXIAM Therapeutics-$240KN/AN/AN/AN/AN/AN/AN/AN/ASHPHShuttle Pharmaceuticals-$11.72M-$47.70N/AN/AN/AN/A-408.34%-138.15%N/ALatest SHPH, CMMB, PHXM, and MTEX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CMMBChemomab Therapeutics-$0.04-$0.22-$0.18$0.24N/AN/A5/14/2026Q4 2025MTEXMannatechN/A$0.49N/A$0.49N/A$24.92 million4/15/2026Q4 2025MTEXMannatechN/A-$5.94N/A-$5.94N/A$26.64 million3/31/2026Q4 2025SHPHShuttle PharmaceuticalsN/A$0.60N/A$0.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCMMBChemomab TherapeuticsN/AN/AN/AN/AN/AMTEXMannatechN/AN/A-100.00%N/AN/APHXMPHAXIAM TherapeuticsN/AN/AN/AN/AN/ASHPHShuttle PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMMBChemomab TherapeuticsN/A10.3110.31MTEXMannatech0.481.090.59PHXMPHAXIAM Therapeutics0.231.78N/ASHPHShuttle PharmaceuticalsN/A0.300.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMMBChemomab Therapeutics46.05%MTEXMannatech12.98%PHXMPHAXIAM Therapeutics0.40%SHPHShuttle Pharmaceuticals4.58%Insider OwnershipCompanyInsider OwnershipCMMBChemomab Therapeutics11.91%MTEXMannatech41.50%PHXMPHAXIAM Therapeutics1.94%SHPHShuttle Pharmaceuticals12.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMMBChemomab Therapeutics207.20 million6.34 millionNot OptionableMTEXMannatech2501.93 million1.13 millionNot OptionablePHXMPHAXIAM Therapeutics493.41 million3.35 millionNo DataSHPHShuttle Pharmaceuticals5637,000557,000Not OptionableSHPH, CMMB, PHXM, and MTEX HeadlinesRecent News About These CompaniesShuttle Pharmaceuticals Announces Planned Reverse Stock SplitJune 11, 2026 | tipranks.comShuttle Pharma Announces Reverse Stock Split will Become Effective on June 11, 2026, at 12:01 a.m., Eastern TimeJune 9, 2026 | newsfilecorp.comNShuttle Pharmaceuticals Holdings Inc SHPHMay 19, 2026 | morningstar.comMShuttle Pharmaceuticals Holdings, Inc.May 15, 2026 | edition.cnn.comShuttle Pharmaceuticals and United Dogecoin Announce Purchase Order for up to 3,000 ElphaPex Dogecoin and Litecoin Mining RigsMay 14, 2026 | newsfilecorp.comNShuttle Pharmaceuticals Completes Merger and PIPE FinancingMay 7, 2026 | tipranks.comE.F. Hutton & Co. Serves as Exclusive M&A Advisor and Placement Agent on Completed Shuttle Pharmaceuticals–United Dogecoin Merger to Create the Largest Public Dogecoin MinerMay 7, 2026 | globenewswire.comShuttle to Acquire United Dogecoin in Push to Build Public DOGE Mining PlatformMay 2, 2026 | finance.yahoo.comWhy is SHPH stock soaring today? Dogecoin mining pivot sparks rallyMay 2, 2026 | msn.comShuttle Pharmaceuticals Transforms into Dogecoin Mining PowerhouseMay 1, 2026 | tipranks.comUnited Dogecoin Goes Public in Landmark Merger, Powering a Scaled, Next Generation DOGE Mining OperationMay 1, 2026 | newsfilecorp.comNShuttle Merges with United Dogecoin to Become the World's Largest Public Dogecoin MinerApril 30, 2026 | newsfilecorp.comNRETRANSMISSION: Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific WorkflowsMarch 27, 2026 | newsfilecorp.comNShuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific WorkflowsMarch 26, 2026 | newsfilecorp.comNE.F. Hutton & Co. Serves as Exclusive Placement Agent on Shuttle Pharmaceuticals’ $3.5 Million Public OfferingMarch 12, 2026 | markets.businessinsider.comE.F. Hutton & Co. Serves as Exclusive Placement Agent on Shuttle Pharmaceuticals' $3.5 Million Public OfferingMarch 12, 2026 | globenewswire.comShuttle Pharmaceuticals Announces $3.5 Million Public OfferingMarch 6, 2026 | newsfilecorp.comNShuttle Pharma Extends Consulting Agreement With Interim Co-CEOFebruary 2, 2026 | tipranks.comUtah Approves AI Prescriptions Drugs. How AI Is Saving Time, Cutting Costs – and Why Molecule.ai's Drug Discovery Platform Matters More Than EverJanuary 13, 2026 | cantechletter.comCUtah Approves AI Prescriptions Drugs. How AI Is Saving Time, Cutting Costs - and Why Molecule.ai's Drug Discovery Platform Matters More Than EverJanuary 13, 2026 | newsfilecorp.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSHPH, CMMB, PHXM, and MTEX Company DescriptionsChemomab Therapeutics NASDAQ:CMMB$1.54 +0.04 (+2.67%) As of 03:58 PM Eastern This is a fair market value price provided by Massive. Learn more.Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.Mannatech NASDAQ:MTEX$5.20 -0.17 (-3.17%) As of 03:37 PM EasternMannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.PHAXIAM Therapeutics NASDAQ:PHXM$3.10 0.00 (0.00%) As of 06/18/2026PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.Shuttle Pharmaceuticals NASDAQ:SHPH$3.67 -0.17 (-4.43%) As of 03:58 PM Eastern This is a fair market value price provided by Massive. Learn more.Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla's New NHTSA Probe Lands at the Worst Possible Time Meta's Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time ASML’s Chip Dominance Runs Into New Silicon Boundaries Frozen Assets: How Super Micro Puts AI Heat on Ice The SpaceX Sell-Off May Be More Than a Market Overreaction Why These South Korea-Focused ETFs Have More Than Doubled in 2026 Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
